These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35264591)

  • 1. 24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy.
    Pérez-Is L; Collazos J; de la Fuente B; Morano L; Rivas-Carmenado M; Rodriguez M; Romero-Favela A; Fonseca-González GJ; Melón S; Valle-Garay E; Asensi V
    Sci Rep; 2022 Mar; 12(1):3828. PubMed ID: 35264591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No gender differences in the 24-month course of non-invasive liver fibrosis markers after DAA therapy in HCV-mono and HCV/HIV-coinfected patients.
    Collazos J; Pérez-Is L; de la Fuente B; Morano L; Rivas-Carmenado M; Rodriguez M; Romero-Favela A; de Jesús Fonseca-González G; Melón S; Diaz-Arias J; Valle-Garay E; Asensi V
    Sci Rep; 2024 Mar; 14(1):7534. PubMed ID: 38553507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors.
    Latronico T; Mascia C; Pati I; Zuccala P; Mengoni F; Marocco R; Tieghi T; Belvisi V; Lichtner M; Vullo V; Mastroianni CM; Liuzzi GM
    Int J Mol Sci; 2016 Mar; 17(4):455. PubMed ID: 27023536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients.
    Suárez-Zarracina T; Valle-Garay E; Collazos J; Montes AH; Cárcaba V; Carton JA; Asensi V
    J Viral Hepat; 2012 Oct; 19(10):685-93. PubMed ID: 22967099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C; Rockstroh JK
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients.
    Laguno M; Martínez-Rebollar M; Casanova M; de Lazzari E; González-Cordón A; Torres B; Inciarte A; Mora L; Ugarte A; Ambrosioni J; Blanco JL; Martínez E; Mallolas J
    Clin Microbiol Infect; 2022 Apr; 28(4):610.e1-610.e7. PubMed ID: 34464735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
    Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
    Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virologic response in hepatitis B and C coinfected persons treated with directly acting antiviral agents: Results from ERCHIVES.
    Butt AA; Yan P; Aslam S; Sherman KE; Siraj D; Safdar N; Hameed B
    Int J Infect Dis; 2020 Mar; 92():184-188. PubMed ID: 31978574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.
    Macías J; Viloria MM; Rivero A; de los Santos I; Márquez M; Portilla J; Di Lello F; Camacho A; Sanz-Sanz J; Ojeda G; Mata R; Gómez-Mateos J; Pineda JA;
    Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):2083-8. PubMed ID: 22258426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.
    Griesbeck M; Valantin MA; Lacombe K; Samri-Hassimi A; Bottero J; Blanc C; Sbihi Z; Zoorob R; Katlama C; Guiguet M; Altfeld M; Autran B;
    AIDS; 2017 Jun; 31(9):1223-1234. PubMed ID: 28492391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of APRI and FIB-4 for confirming cirrhosis in Indonesian HIV/HCV co-infected patients.
    Yunihastuti E; Wicaksana B; Wiraguna A; Hidayah AJ; Amelia F; Natali V; Widhani A; Sulaiman AS; Kurniawan J
    BMC Infect Dis; 2020 May; 20(1):372. PubMed ID: 32450844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection.
    Malin JJ; Boesecke C; Schwarze-Zander C; Wasmuth JC; Schlabe S; Trebicka J; Spengler U; Llibre JM; Jou T; Vasylyev M; Clotet B; Rockstroh JK
    HIV Med; 2019 Mar; 20(3):230-236. PubMed ID: 30687989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis.
    Merchante N; Rivero-Juárez A; Téllez F; Merino D; Ríos-Villegas MJ; Villalobos M; Omar M; Rincón P; Rivero A; Pérez-Pérez M; Raffo M; López-Montesinos I; Palacios R; Gómez-Vidal MA; Macías J; Pineda JA;
    J Antimicrob Chemother; 2018 Sep; 73(9):2435-2443. PubMed ID: 29982683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.
    Behzadpour D; Ahmadi Vasmehjani A; Mousavi Nasab SD; Ahmadi NA; Baharlou R
    Pathog Glob Health; 2016; 110(7-8):310-315. PubMed ID: 27830997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variants upstream of TNFAIP3 in the 6q23 region are associated with liver disease severity in HIV/HCV-coinfected patients: A cross-sectional study.
    Jiménez-Sousa MA; Berenguer J; Fernández-Rodríguez A; Medrano LM; Aldámiz-Echevarria T; Pérez-Latorre L; Díez C; Martín-Vicente M; Gutiérrez-Rivas M; Martínez I; Resino S
    Infect Genet Evol; 2019 Jan; 67():112-120. PubMed ID: 30336268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals.
    Rohrbach J; Stickel F; Schmid P; Thormann W; Kovari H; Scherrer A; Günthard HF; Vuichard D; Cavassini M; Ambrosioni J; Bernasconi E; Furrer H; Rauch A;
    Antivir Ther; 2014; 19(2):149-59. PubMed ID: 24036684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver fibrosis improvement in chronic hepatitis C after direct acting-antivirals is accompanied by reduced profibrogenic biomarkers-a role for MMP-9/TIMP-1.
    Medeiros T; Saraiva GN; Moraes LA; Gomes AC; Lacerda GS; Leite PE; Esberard EB; Andrade TG; Xavier AR; Quírico-Santos T; Rosário NF; Silva AA
    Dig Liver Dis; 2020 Oct; 52(10):1170-1177. PubMed ID: 32522433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
    Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V
    Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients.
    Kennedy A; Hennessy M; Bergin C; Mulcahy F; Hopkins S; Spiers JP
    Antivir Ther; 2011; 16(8):1237-47. PubMed ID: 22155905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
    Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
    Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.